Parmjeet Randhawa

If you edit your contact info this will take to you to your main AST account, and it will take about a half hour for changes to appear.

Contact Details


Dr. Randhawa, Founder Member, and Chair of the Transplant Diagnostics Community of Practice, is a physician-investigator. He runs a research virology laboratory which has been successful in obtaining funding from the NIH as well as the pharmaceutical industry. He mentors technical staff and post-doctoral research fellows. He participates in the teaching of medical students, residents, fellows and visiting physicians who come to observe in the Division of Transplantation Pathology from all over the world. He is the Course Director of a CME Accredited Weekly Allograft Biopsy Conference. He frequently lectures on Transplant Pathology and his laboratory research in national and international forums. As a part of his clinical service he (a) signs native and allograft liver, kidney, heart, pancreas and small intestinal pathology specimens accessioned at the Division of Transplantation Pathology, (b) rotates on the Frozen section service on donor organs referred by the Center for Organ Recovery and Education, and (c) performs immunofluorescence, and electron microscopic evaluation of renal biopsies. His principal administrative responsibility is the Quality assurance review of all renal allograft biopsies, and assignment of coded diagnoses for entry into a computerized database. He serves on the Protocol Review Committee and Data Safety Monitoring Board of the Thomas E Starzl Institute. He is an Associate Editor of the American Journal of Kidney Diseases since 2011. He served as Associate Editor of the American Journal of Transplantation from 2012-2014.Chair Finance Committee, and Member Board of Advisors, The Renal Pathology Society, 2014. Other recent professional service appointments include Co-Chair, Banff Working Group on T-cell mediated acute rejection, Pathology Consultant, LCP-Tacro 3002 Trial in Kidney Transplant Patients, Veloxis Inc., Chair, Cytomegalovirus End Point Adjudication Committee, CMX 001-301 Trial In Hematopoietic Stem Cell Transplant Recipients, Chimerix, Inc, Consultant on “Treatment landscape for polyomavirus BK.” Gerson Lehrman Group Council Member Services, and Member, NIH Grant Review Panel, RFA-AI-12-048, “Immune Mechanisms of Virus Control (U19),